From: Ankylosing Spondylitis News

By: Patricia Inacio, PhD.

 

 

 

 

According to Spherix Global Insights’ survey, which was conducted in March, the main barriers to prescribing Cimzia for nr-axSpA in the U.S. were insurance and cost issues. However, the number of rheumatologists citing these as obstacles has significantly decreased year after year, which highlights the potential widespread use for Cimzia…(read more).